Why the Radoff-JEC bid for Seer is bigger than a small-cap biotech takeover fight
Find out why Seer’s activist battle could reshape investor thinking on proteomics, diagnostics platforms and biotech value creation.
How AstraZeneca’s Owkin deal could push agentic AI deeper into drug development
Pharma has too much data and too little time. AstraZeneca’s Owkin deal tests whether agentic AI can sharpen drug development decisions.
Why Daiichi Sankyo’s Waiv collaboration matters for the next phase of ADC oncology trials
ADC trials need sharper patient selection. Daiichi Sankyo’s Waiv deal tests whether AI pathology can find response signals earlier.
How Tempus AI and Daiichi Sankyo are using real-world data to reshape antibody-drug conjugate development
Tempus AI and Daiichi Sankyo are using multimodal AI to refine ADC trial strategy and biomarker discovery. Read what this could change next.
Parkinson’s disease research shifts toward proteoform-level resolution with Nautilus Biotechnology’s platform
Find out how proteoform-level proteomics could transform Parkinson’s biomarker research and reshape future clinical trials.